Related content

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

By Nissinen E.   Kaheinen P.   Penttila K.E.   Kaivola J.   Linden I.-B.  

European Journal of Pharmacology, Vol. 340, Iss. 2, 1997-12 ,pp. : 287-294

Elsevier

Access to resources Recommend Favorite

Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson’s disease: review and current status

By Gottwald M.D.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 4, 1999-04 ,pp. : 453-462

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg: Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

By Vaz-da-Silva Manuel  

Drugs in R&D, Vol. 9, Iss. 6, 2008-01 ,pp. : 435-446

Adis International

Access to resources Recommend Favorite

Inhibitors of Catechol-O-Methyltransferase

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 324-332

Bentham Science Publishers

Access to resources Recommend Favorite

Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor

By Bonifacio M.J.   Vieira-Coelho M.A.   Soares-da-Silva P.  

European Journal of Pharmacology, Vol. 460, Iss. 2, 2003-01 ,pp. : 163-170

Elsevier

Access to resources Recommend Favorite